染色体末端受到称为端粒的特殊结构的保护，端粒对于维持染色体稳定性和限制细胞生长至关重要。端粒上存在一种名为POT1的蛋白质，它在调节这些保护性末端的长度方面发挥着独特的作用。本文系统地测试了POT1的多种突变，以了解这些变化如何影响端粒的维持。

Foundation – Discovery Stage Research Projects Dr. Joseph C. Wu Base Editing, Single-Cell Multiomics, and Cardiac Organoids to Decode Genetic Variants $4,606,248 Foundation – Discovery Stage Research ...

CIRM funds stem cell research to institutions throughout California. On the map below, click on any marker to learn more about our funding to that institution. You can explore the awards they’ve ...

Welcome to the frequently asked questions (FAQs) page of the California Institute for Regenerative Medicine (CIRM). Here, you’ll find answers to the most common questions you may have on CIRM. CIRM, ...

Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients. CIRM funds clinical trials across a broad ...

When most people think about about stem cells treating disease they think of a stem cell transplant. In a stem cell transplant, stem cells are first specialized into the necessary adult cell type.

Retinal degeneration represents a group of blinding diseases that are increasingly impacting the health and well being of Californians. It is estimated that by 2020, over 450,000 Californians will ...

At the California Institute for Regenerative Medicine (CIRM), we are committed to the continued funding of groundbreaking research in regenerative medicine. To reflect this commitment, we are ...

The following information will help you comply with CIRM regulations and find information about our forms and policies. If you have questions that aren’t addressed on this page contact your Grants ...

The Alpha Clinics Network is funded and supported by the California Institute for Regenerative Medicine (CIRM). The Network features nine world-class medical centers throughout California with a ...

The mission of the California Institute for Regenerative Medicine (CIRM) is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a ...

Jonathan Thomas, PhD, JD, is President and CEO of the California Institute for Regenerative Medicine (CIRM). Thomas was previously the Chair of the CIRM governing Board from June 2011 to March 2023.